MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.5964
-0.0126 (-2.07%)
At close: Aug 4, 2025, 4:00 PM
0.5820
-0.0144 (-2.41%)
Pre-market: Aug 5, 2025, 8:45 AM EDT
Instructure Holdings Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,727,667
Market Cap
11.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | -5 | -41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTVA News
- 1 day ago - MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - PRNewsWire
- 27 days ago - MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose - PRNewsWire
- 6 weeks ago - MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session - PRNewsWire
- 2 months ago - MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewsWire
- 2 months ago - MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - PRNewsWire
- 2 months ago - MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 3 months ago - MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PRNewsWire